ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1338

Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study

Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Mark Tatangelo3 and Claire Bombardier3, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Health Care, Health Services Research, Infection, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed to the disease itself and related therapies used to manage RA, such as steroids, biologic modified anti-rheumatic drugs (bDMARDs), and targeted synthetic dmards (tsDMARD). In this health care cost study we aimed to measure health care utilization (HCU) and related costs of HZ infections among RA patients from the health care payer perspective.

Methods: Patients with RA were identified from the Ontario Rheumatoid Arthritis Database (ORAD), a population-based registry assembled using a validated algorithm, housed at ICES. Costs were measured from a single universal payer (Ontario Health Insurance Plan) at the patient level, with inpatient visits costed using capitation costing methodology. We included all adult (≥18 years) patients diagnosed with HZ between Jan 1, 2008, and March 31, 2020 (RA with HZ). A matched (control) cohort was identified and included all Ontario RA patients that were not diagnosed with HZ (RA without HZ) during the same period of time. The two cohorts were matched based on sex, date of birth (+/- 3 years) and index date (+/- 60 days of HZ infection). The primary outcome was total HCU cost (in Canadian Dollars) per year, up to 10 years of follow-up (adjusted for 2022 inflation). We also looked at the total number of clinical events (CEs) including the number of hospital admissions, emergency department visits, physician visits and other HCU.  The two cohorts were compared using unadjusted gamma distribution models to assess HCU costs, and unadjusted generalized estimating equations (GEEs) with negative binomial distribution to assess total CEs. 

Results: We identified 15,573 RA patients diagnosed with HZ. The same number of RA patients without a HZ diagnosis were matched to this cohort. The RA with HZ cohort had significantly higher total HCU costs across all 10 years of follow-up (except year 2) compared to the RA without HZ cohort (Figure 1, p< 0.05). The mean total cost ranged from 13,507 CAD at year 1 to 17,120 CAD at year 10 for the RA with HZ cohort compared to 12,651 to 14,534 CAD in the RA without HZ cohort. Physician billing costs and inpatient hospital costs were the largest cost drivers for both cohorts.

Compared to RA patients with HZ, matched RA patients without HZ experienced a significantly lower mean number of total CEs (Figure 2, p< 0.05). The difference in total CEs between cohorts, was the highest one year following a HZ infection. The mean total number of CEs was 28.56 for the RA with HZ cohort compared to 23.4 in the RA without HZ cohort. Physician visits were the main driver for clinical events over the 10 years of follow-up.

Conclusion: In this study we found that HCU costs and total CEs were higher in RA patients with HZ compared to RA patients without HZ. Thus, rheumatologists should consider treatment strategies that minimize the risk of HZ and ensure patients’ vaccinations are up to date.

Supporting image 1

Figure 1. Total health care cost per year for RA with HZ compared with RA without HZ

Supporting image 2

Figure 2. Total clinical visits per year for RA with HZ compared to RA without HZ


Disclosures: M. Movahedi: None; A. Cesta: None; X. Li: None; M. Tatangelo: None; C. Bombardier: Abbvie Canada (OBRI and PsA), 5, Amgen (OBRI), 5, Fresenius Kabi (OBRI and PsA), 5, GSK, 1, 2, GSK (OBRI), 5, Merck/Organon (OBRI), 5, Pfizer (OBRI and PsA), 5, Roche (OBRI), 5, Viatris (OBRI), 5.

To cite this abstract in AMA style:

Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C. Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/health-care-utilization-and-cost-of-herpes-zoster-infection-in-patients-with-rheumatoid-arthritis-a-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-care-utilization-and-cost-of-herpes-zoster-infection-in-patients-with-rheumatoid-arthritis-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology